id	author	title	date	pages	extension	mime	words	sentences	flesch	summary	cache	txt
cord-326725-0jgw083h	Klamroth, Robert	Pathogen inactivation and removal methods for plasma‐derived clotting factor concentrates	2013-09-30		.txt	text/plain	5972	303	41	These measures include selection of donors, screening of donations and plasma pools for markers of infection with known viruses, and a manufacturing process with a high capacity to inactivate and/or remove viruses by selected steps validated for their virus reduction capacity. [7] [8] [9] Although screening for viral markers by serology and virus nucleic acid by nucleic acid testing (NAT) ensures that nearly all plasma units entering production are free of HBV, HCV, and HIV, inactivation and removal steps are necessary to reduce any viruses that may enter the plasma pool during a "window period" before markers can be detected. 46 Although B19V was reduced by dry heat in validation studies, the reduction factor may not be sufficient for complete inactivation of the virus load in the final product; asymptomatic B19V infection was detected in a patient who received FVIII concentrate treated at 80°C for 72 hours.	./cache/cord-326725-0jgw083h.txt	./txt/cord-326725-0jgw083h.txt